このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Rhinomed 過去の業績

過去基準チェック /06

Rhinomedの収益は年間平均-8.2%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間47.3% 27.6%割合で増加しています。

主要情報

-8.2%

収益成長率

12.2%

EPS成長率

Pharmaceuticals 業界の成長	31.2%
収益成長率	27.6%
株主資本利益率	n/a
ネット・マージン	-135.5%
前回の決算情報	30 Jun 2023

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

収支内訳

Rhinomed の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ASX:RNO 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 23	8	-11	12	1
31 Mar 23	9	-9	11	1
31 Dec 22	9	-7	11	2
30 Sep 22	10	-6	10	2
30 Jun 22	10	-5	10	2
31 Mar 22	8	-6	10	1
31 Dec 21	6	-6	9	1
30 Sep 21	5	-8	10	1
30 Jun 21	4	-9	10	1
31 Mar 21	5	-8	10	1
31 Dec 20	5	-7	9	0
30 Sep 20	5	-7	9	0
30 Jun 20	4	-7	9	0
31 Mar 20	4	-8	9	0
31 Dec 19	4	-8	9	0
30 Sep 19	4	-7	8	0
30 Jun 19	3	-6	7	0
31 Mar 19	3	-5	6	0
31 Dec 18	3	-5	6	0
30 Sep 18	3	-5	5	0
30 Jun 18	2	-4	5	0
31 Mar 18	2	-4	5	0
31 Dec 17	1	-5	5	0
30 Sep 17	2	-5	5	0
30 Jun 17	2	-4	5	0
31 Mar 17	2	-5	5	0
31 Dec 16	2	-5	5	0
30 Sep 16	1	-5	5	0
30 Jun 16	1	-6	6	0
31 Mar 16	1	-6	5	0
31 Dec 15	1	-6	5	1
30 Sep 15	1	-6	5	1
30 Jun 15	0	-5	4	1
31 Mar 15	0	-5	3	1
31 Dec 14	0	-5	2	0
30 Sep 14	0	-4	1	0
30 Jun 14	0	-4	1	0
31 Mar 14	0	-4	0	0
31 Dec 13	0	-4	2	0
30 Sep 13	0	-9	2	0
30 Jun 13	0	-15	2	0

質の高い収益: RNOは現在利益が出ていません。

利益率の向上: RNOは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: RNOは利益が出ておらず、過去 5 年間で損失は年間8.2%の割合で増加しています。

成長の加速: RNOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: RNOは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 16% ) と比較することは困難です。

株主資本利益率

高いROE: RNOの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Rhinomed 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06